Several outlets report that the U.S. Food and Drug Administration (FDA) has initiated or is moving ahead with a safety review of mifepristone, the medication used in medication abortion. Forbes, The Hill, CBS News, and Scientific American each cite an administration or FDA-related source indicating the review is underway or has been launched, including a retrospective analysis of available data. The reported review is presented as an opportunity for the Trump administration to reconsider how mifepristone is distributed and used, including whether changes could be pursued for access through mail or telehealth, as well as other distribution methods.
The outlets also note that the review is viewed by opponents of abortion medication as a potential pathway to restrict access, while experts raised by Scientific American warn that the approach could sidestep established medical evidence. Across reports, the central points are that FDA is conducting a safety-focused study or review, that it is at an early stage, and that its results could influence future regulatory decisions about mifepristone.
